| 0 (0%) | 09-27 09:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.67 |
1-year : | 3.1 |
| Resists | First : | 2.29 |
Second : | 2.66 |
| Pivot price | 2.26 |
|||
| Supports | First : | 1.7 |
Second : | 1.41 |
| MAs | MA(5) : | 2.13 |
MA(20) : | 2.27 |
| MA(100) : | 2.14  |
MA(250) : | 1.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4 |
D(3) : | 26.6 |
| RSI | RSI(14): 26 |
|||
| 52-week | High : | 2.81 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AYTU ] has closed below the lower bollinger band by 12.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 33.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.68 - 1.69 | 1.69 - 1.7 |
| Close: | 1.72 - 1.74 | 1.74 - 1.76 |
Sat, 27 Sep 2025
What analysts say about AYTU stock - Bollinger Bands Signals & Small Capital Trading Plans - Early Times
Thu, 25 Sep 2025
Maxim Group Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Thu, 25 Sep 2025
Aytu BioPharma (AYTU) Receives Rating Update from Ascendiant Cap - GuruFocus
Thu, 25 Sep 2025
New Analyst Forecast: $AYTU Given $12.5 Price Target - Quiver Quantitative
Thu, 25 Sep 2025
Aytu BioPharma Loses US$2.3m Market Value But Insiders See Windfall Of US$58k - simplywall.st
Wed, 24 Sep 2025
Aytu BioPharma’s Optimistic Earnings Call Highlights ExuA Launch - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 9 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 38 (%) |
| Shares Short | 464 (K) |
| Shares Short P.Month | 585 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.65 |
| Profit Margin | 2 % |
| Operating Margin | 13.1 % |
| Return on Assets (ttm) | -0.6 % |
| Return on Equity (ttm) | -3.1 % |
| Qtrly Rev. Growth | 31.6 % |
| Gross Profit (p.s.) | 5.88 |
| Sales Per Share | 9.09 |
| EBITDA (p.s.) | 0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.17 |
| PEG Ratio | 0 |
| Price to Book value | 0.3 |
| Price to Sales | 0.19 |
| Price to Cash Flow | -2.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|